Phaseline

Targets › FDPS

FDPS (Farnesyl pyrophosphate synthase): drug programs, companies and trials

26 programs from 24 companies in 26 trials: 10 Phase 4, 7 Phase 1, 5 Phase 2, 4 Phase 3; Oncology, Metabolic and endocrine, Other; next expected readout Dec 2026.

Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. (UniProt, P14324)

Open in Phaseline: the race on FDPS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital for Special Surgery, New YorkRisedronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Osteogenesis ImperfectaJan 2027
Aarhus University HospitalZoledronic Acid Anhydrous
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Osteoporosis, PostmenopausalFeb 2027
Shanghai Pulmonary Hospital, Shanghai, ChinaVγ2Vδ2 T lymphocyte-based immunotherapy (zoledronic acid/interleukin 2)
Drug combination that amplifies Vγ2Vδ2 T cells via zoledronic acid (FDPS inhibitor) and IL
IL2, FDPSPhase 4MDR-TBAug 2027
Wake Forest University Health SciencesAlendronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Bone LossJan 2028
University of AarhusZoledronic acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Primary HyperparathyroidismFeb 2028
Chinese University of Hong KongAlendronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4ACL ReconstructionJul 2028
Hadassah Medical OrganizationZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4HIV Infected IndividualsDec 2028
Odense University HospitalAlendronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Osteoporosis in Post-menopausal WomenMar 2029
National Taiwan University HospitalIbandronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Postmenopausal OsteoporosisAug 2030
National Taiwan University HospitalZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 4Postmenopausal OsteoporosisAug 2030
UNICANCERzoledronic acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 3SarcomaDec 2026
St. Louis UniversityZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 3Giant Cell Tumor of BoneJan 2027
Wake Forest University Health SciencesRisedronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 3Bone LossApr 2028
Sherief Abd-Elsalamalendronate sodium
Farnesyl diphosphate synthase inhibitor
FDPSPhase 3Beta Blocker ToxicityOct 2030
Australian and New Zealand Intensive Care Research CentreZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 2Critical IllnessFeb 2027
National Institute of Allergy and Infectious Diseases (NIAID)Alendronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 2HIVMar 2027
University of California, DavisAlendronate Sodium
Farnesyl diphosphate synthase inhibitor
FDPSPhase 2Sickle Cell DiseaseSep 2027
Harbin Medical UniversityRisedronate Sodium
Bisphosphonate; targets farnesyl diphosphate synthase (FDPS) in the mevalonate pathway to
FDPSPhase 2Breast Cancer Triple Negative Breast CancerMar 2028
AUVA Traumazentrum Vienna Site UKH MeidlingZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 2OrthopedicsDec 2030
University of Wisconsin, MadisonZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1Acute Myeloid LeukemiaDec 2026
Emory UniversityZoledronic Acid Anhydrous
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1NeuroblastomaDec 2026
Institute of Hematology & Blood Diseases Hospital, Chinazoledronic acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1Congenital Dyserythropoietic Anemia (CDA)Feb 2027
Children's Hospital Medical Center, CincinnatiZoledronic Acid Anhydrous
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1Hematopoietic Stem Cell TransplantationJan 2028
Mohammed MilhemZoledronic Acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1ChondrosarcomaMay 2028
University of FloridaZoledronic acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1NeuroblastomaFeb 2030
Qilu Hospital of Shandong Universityzoledronic acid
Farnesyl diphosphate synthase inhibitor
FDPSPhase 1Cancer of Stomach, Adenocarcinoma–

Conditions

Neuroblastoma (2) Bone Loss (2) Postmenopausal Osteoporosis (2) Sickle Cell Disease (1) Breast Cancer Triple Negative Breast Cancer (1) Osteogenesis Imperfecta (1) Congenital Dyserythropoietic Anemia (CDA) (1) Beta Blocker Toxicity (1) MDR-TB (1) HIV Infected Individuals (1) Critical Illness (1) Sarcoma (1)

Modalities

small molecule (21), mixed (2), other (1), antibody (1)

Companies

Wake Forest University Health Sciences (2) National Taiwan University Hospital (2) University of Florida (1) University of California, Davis (1) Harbin Medical University (1) Hospital for Special Surgery, New York (1) Institute of Hematology & Blood Diseases Hospital, China (1) Sherief Abd-Elsalam (1) Shanghai Pulmonary Hospital, Shanghai, China (1) Hadassah Medical Organization (1) Australian and New Zealand Intensive Care Research Centre (1) Emory University (1) UNICANCER (1) Aarhus University Hospital (1) University of Aarhus (1) St. Louis University (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Odense University Hospital (1) AUVA Traumazentrum Vienna Site UKH Meidling (1) Qilu Hospital of Shandong University (1)

Related targets

IL2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.